Announcements Trials
Browse Landscape

Phase

Phase 1 26Phase 3 21Phase 1/2 14Phase 2 13Phase 4 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Solid Tumors 1Breast Neoplasms 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × ribociclib × Clear all
NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Pfizer

Phase 4 Recruiting
46 enrolled
Other solid neoplasm

Solid Tumors

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Novartis

Phase 4 Active not recruiting
134 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡